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ABSTRACT 
The purpose of this study was to compare the effects of propranolol, timolol and bevacizumab with betamethasone to 
prevent corneal neovascularization (CNV) in rabbits. This study was performed on 28 male rabbits. CNV was induced by 
three 7-0 silk sutures 2 mm long and 1 mm distal to the limbus. Animals were randomly divided into 4 groups of 
propranolol + betamethasone, timolol + betamethasone and bevacizumab + betamethasone and betamethasone alone. 
Eye drops were started from the first day of study. On 7th, 14th, 21st, 28th, 35th and 42nd days, vascular progression, time of 
neovascularization and vascular area were evaluated and compared with the control group (betamethasone alone). 
There was a significant reduction in the area of neovascularization in the timolol and bevacizumab groups compared to 
the control group (P-value = 0.05, P=0.047, respectively). Also, regarding vascular progression, there was a significant 
decrease in the timolol and bevacizumab groups (P-value = 0.014, P=0.002, respectively). Regarding delayed onset of 
neovascularization, there was a significant difference in the timolol and bevacizumab group in rabbits (P-value = 0.04, 
P=0.00, respectively). In conclusion, the use of timolol and bevacizumab drops besides betamethasone can delay 
neovascularization and decrease the length of corneal vascularization in rabbits. 
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INTRODUCTION
The cornea is a clear and avascular structure 
essential to create a proper anterior refractive 
surface [1]. Corneal disease is the third most 
common cause of impaired vision worldwide. 
Although the prevalence and incidence of corneal 
neovascularization (CNV) are unknown globally, it is 
predictable that 1.4 million people develop CNV 
yearly, and vision loss occurs in 12% of them [2]. CNV 
is caused by a variety of etiologies, such as 
hereditary diseases, contact lens hypoxia, 
inflammatory conditions, chemical burns, stem cell 
deficit, allergies, ocular trauma, infectious keratitis, 
autoimmune diseases and corneal transplant 
rejection [3]. Neovascularization of the cornea 
involves sprouting of new vessels, especially of the 
capillaries and venules around the cornea. 
Development of new and uncontrolled vessels in the 
eye is an important process in the pathogenesis of 
various types of eye diseases including Herpes virus 
keratitis, diabetic retinopathy, and age-related 
macular degeneration, as well as chemical and 
physical injuries [4].  
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In the pathogenesis of CNV, the balance between 
proangiogenic and anti-angiogenic factors is 
disrupted, which induces expression of Vascular 
endothelial growth factor (VEGF) [5]. The VEGF factor 
and its dependent molecules seem to play a key role 
in signal regeneration of the neovascularization 
process [6]. Various medications or surgeries are 
used in the management of CNV. There are several 
methods available for the management of CNV 
including corticosteroids, cyclosporine, bevacizumab, 
ranibizumab, non-steroidal anti-inflammatory drugs, 
systemic methotrexate and thalidomide [7]. These 
treatments have side effects and sometimes patients 
are not satisfied with these medications. In the 
recent years, there has been a great interest in the 
management of CNV by anti-VEGF (drops, 
subconjunctival and intra-stromal) [2]. Bevacizumab 
(monoclonal anti-VEGF) is commonly used for the 
treatment of CNV pre- and postoperatively [8]. 
Bevacizumab is widely used for the treatment of 
various diseases such as colorectal cancers. 
Intravitreal injection of bevacizumab is used in the 
treatment of macular degeneration, choroidal 
neovascularization and diabetic retinopathy [9, 10]. 
Early injection of bevacizumab may inhibit CNV, while 
late injection of bevacizumab may not alter 
macrophage infiltration and cannot prevent 
expression of VEGF, VEGFR1 and VEGFR2 on corneal 
vessels [11]. 
Propranolol is a non-selective beta-adrenergic 
receptor blocker commonly used in cardiovascular 
diseases such as ventricular tachyarrhythmia and 
hypertension. In some studies, propranolol has been 
shown to have anti-angiogenic and vasoconstrictive 
effects by inhibiting vascular factors such as VEGF 
and Fibroblastic growth factor (FGF), making it a 
target for treatment and control of retinal 
neovascular diseases [12]. Due to presence of VEGF 
receptors on the surface of corneal endothelial cells, 
the possibility of drug effects on corneal endothelial 
cells has been suggested [13]. Timolol and 
propranolol are similar in some aspects as both of 
them are non-selective beta-adrenergic antagonists. 
The mechanism by which these medicines act on 
neovascularization regression is mainly indefinite. 
Nevertheless, these medicines are thought to act 
over VEGF signaling, vasoconstriction and vascular 
endothelial cell apoptosis [14, 15].  
Steroids are commonly used in ophthalmology as a 
potent anti-inflammatory agent. They are mainly 
inhibited by phospholipase enzyme and thus by the 
arachidonic acid pathway (reduced production of 
prostaglandins). Some prostaglandins exert indirect 
anticoagulant effects [16]. Some previous studies on 
CNV have been performed using propranolol, timolol 
and bevacizumab [12, 15, 17, 18]. Owing to pivotal 
role of corneal transparency and avascularity in 
optimal visual quality, this study aimed to compare 
the effect of propranolol, timolol and bevacizumab 
with betamethasone in prevention of CNV in rabbits. 
 
METHODS 
This experimental animal study was performed on 28 
male rabbits weighing 1500-1900 grams and aged 
one year approximately (Animal Care Center of Ahvaz 
Jundishapur University of Medical Sciences). Animals 
were kept individually in standard cages at optimal 
room temperature with appropriate ventilation and 
fed with pellet feed and water for a week to adapt to 
the new environment. They were kept under twelve 
hours of light and twelve hours of darkness. The 
animal's right eye selected for the study. All tenets of 
the Declaration of Helsinki regarding animal studies 
were considered. The study was approved by the 
Ethics Committee of Ahvaz Jundishapur University of 
Medical Sciences (Code, IORC-9702).  
At first, animals were sedated using intramuscular 
injection of ketamine (Ketalar; Par Pharmaceutical 
Co, Inc., The USA) (20mg/kg) and xylazine (Xylazine; 
Pantex Holland B.V) (2mg/kg). The evaluation was 
performed by an ophthalmology resident using a slit 
lamp (Topcon SL-5D; Kogaku Kikai K. K., Tokyo, 
Japan). Induction of CNV was performed by three 
loose vertical sutures with 7-0 silk (Supasil, Supa 
Medical Devices, Iran) approximately 2 mm long and 
1 mm distal to the limbus in three areas. All surgeries 
were performed by one person (MS.M.). 
Ciprofloxacin eye drops 0.3% (Ciplex; Sina Darou 
Laboratories Co) were used every six hours for 2 
weeks to prevent ocular infection. Rabbits were 
randomly divided into 4 groups including control 
group (betamethasone 0.1%, 3 times daily) 
(Betasonate; Sina Darou Laboratories Co), 
propranolol (Pranol; Tolid Daru Co) group 
(betamethasone 0.1%, 3 times daily + propranolol 
10mg/mL, 3 times daily), timolol group 
(betamethasone 0.1% drops 3 times daily + timolol 
0.5% drops, 3 times daily) (Timolol; Sina Darou 
Laboratories Co) and bevacizumab (Avastin; 
Genetech, Inc.) group (betamethasone 0.1% drops 3 
times daily + bevacizumab drops 4 mg/mL, 2 times 
daily) and continued until initiation of 
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neovascularization up to 6 weeks. Rabbits were 
examined on 7
th
, 14
th
, 21
st
, 28
th
, 35
th
 and 42
nd
 days. In 
each examination photography was performed using 
a CANON Camera (5D, MARK3, JAPAN). Progression 
of intra-corneal vessels was assessed in each 
examination. The length of vascular advancement 
(the closest distance from the vessels to the limbus) 
(millimeter; mm) and the level of corneal vascular 
area (square millimeter; mm
2
) (corneal area with 
vessels) were measured with the help of a Cursor. All 
images were evaluated using ImageJ software version 
1.49 (Image processing, NIH, Bethesda, Maryland).  
Descriptive statistics were used for analysis, including 
mean and standard deviation (SD) for quantitative 
variables and relative percentages and frequencies 
for qualitative variables. A Chi-square test was used 
to assess the association between quantitative 
variables. Data analysis was performed using SPSS 22 
software (SPSS Inc., IBM Corporation., Platform Java, 
Type: statistical analysis). 
 
RESULTS 
CNV occurred in the study groups at different weeks. 
Figure 1 shows actual mean of vascular progression, 
the time of neovascularization and vascular area in 
all four groups. At the end of study, vascular 
progression, the time of neovascularization and 
vascular area were evaluated in all the four groups 
compared to the control group (betamethasone 
alone). All the three variables (area, length, and 
time) were recorded in all four groups and compared 
with each other (Table 1). In this study, the area of 
vessels in the propranolol + betamethasone, timolol 
+betamethasone, and bevacizumab + betamethasone 
groups were compared to the control group 
(betamethasone alone). There was a significant 
difference between the three study groups and the 
control group regarding reduction in the area of 
neovascularization in rabbits, which showed a 
significant decrease in the timolol and bevacizumab 
groups (Table 2) (P-value = 0.05, 0.047). On the 42
nd
 
day of study, comparison of the study groups 
regarding the length of neovascularization showed 
significantly less progression in timolol and 
bevacizumab study groups (P-value=0.014, P-
value=0.002) (Table 3). Regarding delayed onset 
neovascularization in the three study groups 
compared to the control group (betamethasone 
alone), there was a significant difference between 
the propranolol, timolol and bevacizumab groups 
compared to the control group (P-value = 0.04, 0.00, 
and 0.00, respectively) (Table 4). Figures 2, 3, 4, 5 
show the progression and area of CNV in the study 
groups at 7
th
, 21
st
 and 42
nd
 days of study. In the last 
photo of each figure (42
nd 
day) specifically in the 
control group, a dominant increase of length and 
area of CNV is seen.  
 
 
Figure1: Actual Mean of Vascular Progression, the Time of Neovascularization and Vascular Area in Four Study Groups. Abbreviations: CNV: Corneal 
Neovascularization; Length of CNV: Mean in millimeter.  
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Table1: Mean Rank of Three Variables of Corneal Neovascularization in the Four Study Groups 
Table 2: Reduction in the Area of Corneal Neovascularization (percentage) in the Three Study Groups Compared to the Control Group. 
P value less than 0.05 in bold. 
Table 3: Length of Corneal Neovascularization (millimeter) in the Three Study Groups Compared to the Control Group. 
P value less than 0.05 in bold. 
 
Table 4: Delayed Onset Corneal Neovascularization in the Three Study Groups Compared to the Control Group. 
P value less than 0.05 in bold. 
 
 
 
 Groups Number Mean Rank 
Time; days Betamethasone 7 5.64 
Propranolol + Betamethasone 7 12.50 
Timolol + Betamethasone 7 20.64 
Bevacizumab + Betamethasone 7 19.21 
Total 28  
Area;  square millimeter Betamethasone 7 23.64 
Propranolol + Betamethasone 7 15.64 
Timolol + Betamethasone 7 10.07 
Bevacizumab + Betamethasone 7 8.64 
Total 28  
Length; millimeter Betamethasone 7 21.29 
Propranolol + Betamethasone 7 18.29 
Timolol + Betamethasone 7 10.50 
Bevacizumab + Betamethasone 7 7.93 
Total 28  
(I) groups (II) groups Mean Difference  p-value 95% Confidence Interval 
Lower Bound Upper Bound 
Betamethasone Propranolol + Betamethasone 5.14 0.085 -3.63 13.91 
Timolol + Betamethasone 8.71 0.050 -0.06 17.49 
Bevacizumab + Betamethasone 9.29 0.047 0.51 18.06 
(I) groups (II) groups Mean Difference  p-value 95% Confidence Interval 
Lower Bound Upper Bound 
Betamethasone Propranolol + Betamethasone -0.86 0.04 -1.71 0 
Timolol + Betamethasone -1.71 0.00 -2.57 -0.86 
Bevacizumab + Betamethasone -1.57 0.00 -2.42 -0.72 
(I) groups (II) groups Mean Difference  p-value 95% Confidence Interval 
Lower Bound Upper Bound 
Betamethasone Propranolol + Betamethasone 0.25 0.67 -0.37 0.88 
Timolol + Betamethasone 0.75 0.014 0.12 1.38 
Bevacizumab + Betamethasone 0.92 0.002 0.29 1.55 
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Figure 2: Control Group: 7th, 21st and 42nd Days of Study; Significant Progression of Area and Length of corneal neovascularization (CNV) in 42nd Day of 
Study. 
 
 
 
Figure 3: Propranolol Group: 7th, 21st and 42nd Days of Study; Progression of Area and Length of corneal neovascularization (CNV) in 42nd Day of Study 
Compared to the Control Group. 
 
 
Figure 4: Timolol group: 7th, 21st and 42nd Days of Study; Significant Less Progression of Area and Length of corneal neovascularization (CNV) in 42nd Day 
of Study Compared to the Control and Propranolol Groups. 
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Figure 5: Bevacizumab Group: 7th, 21st and 42nd Days of Study; Significant Less Progression of Area and Length of CNV in 42nd Day of Study Compared 
to Control and Propranolol Groups 
 
DISCUSSION 
There was a significant decrease in the area of 
neovascularization in the timolol and bevacizumab 
groups (P-value = 0.05, and 0.047, respectively). 
Regarding length of CNV, there was a significantly less 
progression in the timolol and bevacizumab groups (P-
value = 0.014, and 0.002, respectively). Regarding 
delayed onset of CNV, a significant difference in the 
propranolol, timolol and bevacizumab group was 
observed (P-value = 0.04, 0.00, and 0.00, respectively).  
Imbalance in angiogenesis is an underlying mechanism 
for neovascularization. Vascular endothelial growth 
factor is one of the elements associated with 
neovascularization. Many VEGF inhibitors have been 
used for retinal and some corneal disorders. One of 
important VEGF inhibitors is bevacizumab. Because of 
the efficiency of bevacizumab as an anti-VEGF, it has 
been considered as a potential management choice for 
neovascularization on the cornea [19]. Bevacizumab 
prevents interaction between VEGF-A and its receptors 
(VEGFR-1 and VEGFR-2). Rocher et al. found a 
comparable result to our study in gerbils. Compared to 
the control group, subconjunctival injection of a 150 kDa 
rat anti-VEGF antibody (0.02 mL 10µg/mL) reduced the 
neovascularization area by more than 20%, while topical 
application (10µg/mL) reduced it by 15% [20]. Given the 
presence of VEGF receptors on the surface of corneal 
endothelial cells, the possibility of drug effects on corneal 
endothelial cells has been suggested [21, 22]. Luis de 
Redin et al. evaluated the effect of bevacizumab-loaded 
albumin nanoparticles in a rat model of CNV. Results 
established by histopathological analysis clearly revealed 
that eyes treated with nanoparticles displayed lower 
levels of fibrosis, inflammation and edema [23]. 
Baradaran-Rafii A et al. conducted a study to compare 
Adiponectin versus bevacizumab eye drops for the 
treatment of CNV during 14 days. Results showed 
reduction of CNV in both groups but more in Adiponectin 
[24]. Sahan B et al. compared the inhibitory effects of 
dovitinib and bevacizumab for the treatment of CNV in a 
rat model and showed a statistically significant decrease 
in the percentage of CNV in all the treatment groups, 
which was not statistically significant in the percentage 
of CNV between bevacizumab and bevacizumab 
+dovitinib groups [25]. Study of Xu X et al. on prevention 
of CNV by subconjunctival injection of bevacizumab 
loaded thermosensitive hydrogels in rabbits confirmed 
the effect of bevacizumab in the treatment of CNV. They 
also suggested that proposed Ava-PECE hydrogel might 
be a capable vehicle for the treatment of CNV [26]. Lopes 
GJA et al. showed the inhibitory effect of topical 
application and subconjunctival injection of bevacizumab 
without any significant difference on CNV in rabbits after 
chemical burning of the cornea [27]. Huang J et al. 
concluded that combined Dexamethasone and Avastin 
(bevacizumab) by supramolecular hydrogel exhibited an 
advantage over Avastin monotherapy approach, which 
might be a promising alternative therapy for 
inflammatory CNV [28], which is similar to our results as 
we used combined betamethasone and bevacizumab. 
Sella R et al. and Gal-Or O et al. conducted compared the 
efficacy of topical and Subconjunctival Aflibercept with 
Bevacizumab for the prevention of CNV in a rat model. 
They concluded that aflibercept effectively inhibits CNV 
in a rat model of chemical burn-induced 
neovascularization and has more efficacy compared to 
bevacizumab [29, 33]. These two studies confirmed the 
effect of anti-VEGF agents in the treatment of CNV, but 
on the other side showed a less effect of bevacizumab. 
Moreover, Ozdemir O et al. revealed that both 
subconjunctival and topical administrations of 
bevacizumab prevent CNV and reduce inflammation and 
fibroblast activity in a rat model. Also, they did not find 
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significant differences between subconjunctival injection 
and topical administration of bevacizumab [30], which is 
consistent with a meta-analysis performed by 
Papathanassiou M et al. They concluded that both topical 
and subconjunctival bevacizumab accomplish a 
significant decrease in the area of CNV [31]. In this study, 
CNV was induced by alkali burn, but we used corneal 
suturing to induce the CNV. Our study was in the line 
with abovementioned studies in part which showed the 
effect of anti-VEGF agents, specifically bevacizumab, in 
the treatment of CNV.  
Side effects of timolol include blinking, burning, staining, 
itching, redness or pain in the eye and headaches [32]. 
Propranolol with its anti-vascularization and 
vasoconstriction effects and also inhibition of VEGF and 
FGF might control retinal neovascular diseases [34]. 
However, Filippi L et al. reported two patients with CNV 
due to Stevens-johnson syndrome complications, who 
did not respond to steroids and cyclosporine well. They 
showed a positive effect of propranolol eye drops in the 
treatment of CNV, which is in line with the present study 
[35]. The results of our study can provide useful 
information for effective improvement or prevention of 
CNV. In the study of Simavli et al. in 24 eyes of 24 mice, 
neovascularization of the cornea was induced using 
NaOH. They showed that the mean percentage of CNV in 
the first group (treated with normal saline drops) was 
59%, in the second group (treated with dexamethasone 
drops) 25.5%, in the third group (treated with 
propranolol 1 mg/mL drops) 68.9% and in the fourth 
group (treated with propranolol 0.5 mg/mL drops) 50.4%. 
There was no significant difference between the third 
and fourth groups with the first group. Whereas the 
second group had significantly less CNV area than the 
other groups. They concluded that topical propranolol at 
a dose of 1 and 0.5mg/mL did not affect NaOH-induced 
CNV in mice [12]. Similar to the present study, no 
significant reduction in neovascularization after 
treatment with propranolol was observed in mice, which 
confirms the results of our study. However, propranolol 
combined with betamethasone eye drop delayed CNV 
onset compared with betamethasone eye drop alone.  
Kasiri et al. conducted a study to inhibit CNV by timolol in 
the rabbit model. Neovascularization was induced in the 
eyes of 20 rabbits and then divided into two groups; the 
timolol group received 0.5% timolol eye drops twice 
daily, and the control group received saline drops two 
times per day for two weeks. The mean CNV area after 7 
days was significantly lower in the timolol group than the 
saline group (P <0.001). After 2 weeks, the mean CNV in 
the timolol group were 1.33 ± 0.85 and 2.06 ±1.73, 
correspondingly (P = 0.315). After the first week of 
treatment, timolol significantly reduced CNV compared 
to controls [15]. which is consistent with the current 
study regarding the efficacy of timolol in improvement 
and prevention of CNV.  
Furthermore, Öner et al. randomly divided 20 rats with 
silver nitrate induced CNV into four groups. The control 
group received artificial tears twice daily, the second 
group received subconjuctival bevacizumab in the first, 
fourth and seventh days, and the other two groups 
received topical bevacizumab at doses of 4 and 12.5 
mg/mL twice weekly. The results showed that the mean 
percentage of CNV was 63% in the control group, 30% in 
the injected bevacizumab group and 27% and 26% in the 
other two groups. In this study, a significant difference 
was observed between the control and other groups (p 
<0.01). They concluded that subconjunctival injection 
and topical administration of bevacizumab are effective 
and safe in the control of CNV [17]. It is consistent with 
our results which showed that bevacizumab and timolol 
were effective in decreasing neovascularization area (P-
value: 0.05,0.047) and decreasing neovascularization 
length (P-value: 0.014, 0.002) compared to 
betamethasone as a control group.  
In a case-series study on 5 patients by Felix Bock to 
evaluate the effect of bevacizumab on CNV, patients with 
invasive CNV were treated with conventional 
bevacizumab eye drops (0.5 mg/mL) for 6 months. In this 
study, neovascularization decreased significantly in all 
patients with bevacizumab, which is consistent with our 
study [18]. Moreover, Mohammad Dastjerdi evaluated 
the efficacy and safety of bevacizumab to treat CNV. He 
evaluated 10 eyes of 10 patients and followed them for 6 
months. Their results showed safety and efficacy of 
bevacizumab in reducing CNV, which is similar to ours 
[8].  
One of the innovations of this study was the use of 
medications concomitantly with betamethasone, to 
compare the efficacy of these drugs (propranolol, timolol 
and bevacizumab drops) with the control group 
(betamethasone alone). Other innovations in this study 
were the timing of drug administration at baseline as 
well as not removing sutures as an angiogenic 
stimulatory factor. We had some limitations. This study 
was performed with a relatively small number of 
laboratory animals. Other limitations of this study include 
failure to evaluate antibiotic susceptibility and drug 
resistance, failure to evaluate side effects, and severity of 
symptoms. Further clinical trials may indicate the efficacy 
of these drugs in human more clearly. Therefore, further 
controlled studies are needed to understand the effects 
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of propranolol, timolol and bevacizumab eye drops in the 
treatment of CNV. 
CONCLUSION 
Timolol and bevacizumab eye drops could delay and 
inhibit neovascularization and decrease the length of 
CNV in rabbits. Further controlled studies are needed to 
understand the effects of propranolol, timolol and 
bevacizumab eye drops in the treatment of CNV. 
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